Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -2215.4%
Operating margin was -2215.4% in Q1 FY2026, down 1755.1 pp from a year earlier. On a trailing-twelve-month basis it was -319.2%, down 190.5 pp year over year. Over 3 fiscal years it narrowed by 92.2 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 1 analysts of -93.5% for the fiscal year ending Dec 2026, up from -273.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -2215.4%-2039.9 pp QoQ
- Last fiscal yearDec 2025
- -273.1%-93.2 pp YoY
- LTMMar 2026
- -319.2%-190.5 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -273.1%
- Year-over-year change
- -93.2pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -273.1% | -93.2pp |
| FY2024 | 2024-12-31 | -179.9% | -24.4pp |
| FY2023 | 2023-12-31 | -155.5% | +25.4pp |
| FY2022 | 2022-12-31 | -180.8% | -15.2pp |
| FY2021 | 2021-12-31 | -165.6% | — |
Operating Margin vs competitors
How SGMO compares with its peers on the latest reported figures
- SGMO's LTM Mar 2026 operating margin of -319.2% is the 4th highest of the 10 companies compared; the peer median is -1093.0%.
- Its year-over-year change of -190.5 pp is the 6th highest of 9, against a peer median of +15.4 pp.
- Over three fiscal years its change of -92.2 pp compares with a peer median of -29.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -33.2% | +101.6 pp | -29.3 pp | |
| LTM Mar 2026 | -146.4% | +256.2 pp | — | |
| LTM Mar 2026 | -200.3% | +64.4 pp | -338.0 pp | |
| LTM Mar 2026 | -319.2% | -190.5 pp | -92.2 pp | |
| LTM Mar 2026 | -326.6% | -33.6 pp | +125.9 pp | |
| LTM Mar 2026 | -1093.0% | +3181.5 pp | — | |
| LTM Mar 2026 | -1258.6% | -398.8 pp | +34.1 pp | |
| FY2025 | -1916.9% | -1508.3 pp | -1817.4 pp | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -2112.4% | -588.3 pp | +1124.5 pp |
| LTM Mar 2026 | -3669.4% | — | -2848.9 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding SGMO) | -1093.0% | +15.4 pp | -29.3 pp | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 110.7M | 111.3M | 176.23M | 57.8M | 39.55M |
| Cost of Revenue | 0 | 12.11M | 0 | 0 | 7.6M |
| Gross Profit | 110.7M | 99.19M | 176.23M | 57.8M | 31.95M |
| Gross Margin | 100.0% | 89.1% | 100.0% | 100.0% | 80.8% |
| Research & Development | 230.82M | 249.9M | 234.06M | 111.52M | 112.67M |
| Selling, General & Admin | 63.22M | 62.68M | 61.17M | 44.73M | 34.89M |
| Operating Expenses | 294.04M | 300.47M | 450.24M | 161.77M | 139.95M |
| Depreciation & Amortization | 17.64M | 12.11M | 22.19M | 9.36M | 7.6M |
| EBITDA | (160.35M) | (179.74M) | (96.8M) | (89.09M) | (115.9M) |
| EBITDA Margin | -144.9% | -161.5% | -54.9% | -154.1% | -293.0% |
| Operating Income | (183.34M) | (201.28M) | (274.01M) | (103.97M) | (108M) |
| Operating Margin | -165.6% | -180.8% | -155.5% | -179.9% | -273.1% |
| Interest Income | 5.35M | 9.43M | 11.1M | 5.86M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.35M | 9.43M | 11.1M | 5.86M | (15.5M) |
| Income Before Tax | (177.99M) | (191.85M) | (262.9M) | (98.11M) | (123.5M) |
| Pre-Tax Margin | -160.8% | -172.4% | -149.2% | -169.7% | -312.2% |
| Income Tax Expense | 306K | 429K | (5.07M) | (167K) | (568K) |
| Net Income | (178.29M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Net Margin | -161.1% | -172.8% | -146.3% | -169.4% | -310.8% |
| EPS (Basic) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| EPS (Diluted) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| Weighted Avg Shares | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
| Weighted Avg Shares (Diluted) | 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.